fda semaglutide approval The #FDA approved the first oral GLP-1 receptor agonist, (#Wegovy pill), for chronic weight management in adults with obesity or overweight with comorbidities, offering a noninjectable alternative with significant weight loss FDA Approves Semaglutide for New

A brief review was conducted to explore current evidence on the interaction between GLP-1RAs and gut microbiotatermed the pharmaco-gut axis. Literature was examined to understand how specific microbial populations affect drug efficacy and insulin sensitivity

Explore the link between Ozempic and sugar excretion in urine

If it was a digestive side effect, you name it, and I had it

2020 global estimate and projected number of adults through 2035 with an overweight BMI [1]. Obesity is a significant independent risk factor contributing to numerous chronic conditions, including diabetes, hypertension, cardiovascular disease, and obstructive sleep apnea syndrome

As a trusted supplier, Saif Pharma ensures seamless distribution